Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News InVivo Therapeutics Holdings Corp NVIVQ

Healthcare Medical Devices
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries (SCIs). The Company's Neuro-Spinal Scaffold implant is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. It is intended to promote appositional, or side-by... see more

Recent & Breaking News (OTCPK:NVIVQ)

InVivo Therapeutics Holdings Corp. Announces Proposed Public Offering

Business Wire May 5, 2014

FDA Approves Clinical Trial of BrainStorm Cell Therapeutics' ALS Treatment

Accesswire April 29, 2014

InVivo Therapeutics Initiates First Clinical Trial of Neuro-Spinal Scaffold

Business Wire April 28, 2014

InVivo Therapeutics Reports 2013 Financial Results and Business Update

Business Wire March 17, 2014

InVivo Therapeutics Names Tamara L. Joseph as Its General Counsel and Chief Compliance Officer

Business Wire March 17, 2014

InVivo Therapeutics Names Thomas R. Ulich, MD as Its New Chief Scientific Officer

Business Wire February 24, 2014

InVivo Sends Amended Protocol to FDA and Six Clinical Sites

Business Wire January 3, 2014

TrendingWallStreet.com Initiates Trend Alerts on CSCO, CLF, NVIV, and ZNGA

Accesswire December 30, 2013

InVivo Announces Regulatory and Clinical Promotions

Business Wire December 27, 2013

InVivo Therapeutics to Move Forward with Its First Clinical Trial After Receiving FDA Conditional Approval

Business Wire December 26, 2013

InVivo Names Mark Perrin as Its New Chief Executive Officer

Business Wire December 23, 2013

InVivo Therapeutics Appoints Steven McAllister as Interim CFO

Business Wire December 16, 2013

InVivo Therapeutics Announces Promotions in Technical Operations

Business Wire December 9, 2013

TrendingWallStreet.com Puts Out High Volume Alerts on TSL, DECN, NVIV, and AMRN

Accesswire November 20, 2013

InVivo Therapeutics Appoints Christopher McNulty as Vice President, Business Development

Business Wire November 18, 2013

TrendingWallStreet.com Initiates Analysis on FENG, NVIV, LIFS, and ZNGA

Accesswire November 18, 2013

InVivo Therapeutics Lead Program on Track

Business Wire November 15, 2013

News and Updates on CTIX, CERP, NVIV and TRTC

Accesswire November 12, 2013

Small Cap Equity Reports on NVIV, SCRC and WDDD

Accesswire October 28, 2013

New In-Depth Stock Reports on BMSN, CERP, NAMG and NVIV

Accesswire October 25, 2013